PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.3032018503835-842Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid TumorsTae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Banghttp://e-crt.org/upload/pdf/crt-2017-303.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.303, http://www.e-crt.org/upload/pdf/crt-2017-303.pdf
Annals of Oncology10.1093/annonc/mdy53220193061020Corrections to “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors”J.-C. Soria, J. Cortes, C. Massard, J.-P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J.-F. Marier, M. Beliveau, R.E. Martell, J. Baselgahttps://api.elsevier.com/content/article/PII:S0923753419311913?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419311913?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/6/1020/28871726/mdy532.pdf
Annals of Oncology10.1093/annonc/mdr1372012232463-471Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumorsJ.-C. Soria, J. Cortes, C. Massard, J.-P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J.-F. Marier, M. Beliveau, R.E. Martell, J. Baselgahttps://api.elsevier.com/content/article/PII:S0923753419343959?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419343959?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/23/2/463/552554/mdr137.pdf
European Journal of Cancer10.1016/s0959-8049(02)80854-1200238S64EKB-569, an irreversible inhibitor of the epidermal growth factor receptor: Phase 1 trial results in patients with advanced solid tumorshttps://api.elsevier.com/content/article/PII:S0959804902808541?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804902808541?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdz244.034201930v178A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumoursA.C. Tan, A.O.L. Seet, S.P. Choo, D.W.M. Tai, Y.C.J. Lam, W.T. Teng, C. Lim, K.H. Lim, M.C.H. Nghttps://api.elsevier.com/content/article/PII:S092375341958694X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375341958694X?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz244.034/30081368/mdz244.034.pdf
Cancer Chemotherapy and Pharmacology10.1007/s00280-014-2621-7201475197-109Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignanciesYook-Hwan Noh, Hyeong-Seok Lim, Jin-A Jung, Tae Hun Song, Kyun-Seop Baehttp://link.springer.com/content/pdf/10.1007/s00280-014-2621-7.pdf, http://link.springer.com/article/10.1007/s00280-014-2621-7/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-014-2621-7
Breast Cancer Research10.1186/bcr2280200911S1Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancerH Cortés-Funes, C Mendiola, L Manso, E Cirueloshttp://link.springer.com/content/pdf/10.1186/bcr2280.pdf, http://link.springer.com/article/10.1186/bcr2280/fulltext.html, http://link.springer.com/content/pdf/10.1186/bcr2280.pdf
Annals of Oncology10.1016/s0923-7534(20)32010-x201223xi34First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung CancersM.G. Kris, T. Mok, S.-H.I. Ou, R.G. Martins, D.-W. Kim, Z. Goldberg, H. Zhang, I. Taylor, S.P. Letrent, P.A. Jännehttps://api.elsevier.com/content/article/PII:S092375342032010X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375342032010X?httpAccept=text/plain
The Journal of Clinical Pharmacology10.1002/jcph.21742022Population Pharmacokinetics of Mivavotinib (TAK‐659), a Dual Spleen Tyrosine Kinase and FMS‐Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic MalignanciesCheryl Li, Kenny Watson, Shining Wang, Paul Matthias Diderichsen, Neeraj Guptahttps://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2174, https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jcph.2174, https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2174
Investigational New Drugs10.1007/s10637-017-0514-42017363424-434Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumorsTomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, Hidehisa Noguchi, Masayuki Aoki, Toshihiko Doihttp://link.springer.com/article/10.1007/s10637-017-0514-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10637-017-0514-4.pdf, http://link.springer.com/content/pdf/10.1007/s10637-017-0514-4.pdf